Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials

Written by Fanny Elahi

Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes

Fanny Elahi
Previous

Potential contributors to variable penetrance of NOTCH3 p.Arg1231Cys Variant
Next

CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults